Table 1.

Completed and ongoing clinical trials using oncolytic virotherapy as a therapeutic strategy against malignant glioma.

Virus type	Genetic alteration	Target	Study type	Delivery method	Status of clinical trial	Reference
Ad: ONYX-015	E1B-55k deletion	Deficient p53 pathway	Phase I	Tumor bed post-resection	Completed	Chiocca et al., 2004
Ad: Ad5-Delta24RGD	Partial E1A deletion and received RGD motif	Disrupted Rb pathway	Phase I	Intratumoral	Recruiting patients	NCT00805376
Ad: Ad5-Delta24RGD	Partial E1A deletion and received RGD motif	Disrupted Rb pathway	Phase I/II	Intratumoral/CED	Recruiting patients	NCT01582516
Ad: AdV-tk	Thymidine kinase (tk) incorporation	Intracellular activation of prodrugs	Phase IB	Tumor bed post-resection	Completed	Chiocca et al., 2011
Ad: AdV-tk/GCV	Thymidine kinase (tk) incorporation	Intracellular activation of prodrugs	Phase I	Tumor bed post-resection	Completed	Sandmair et al., 2000
RV: RV-tk/GCV	Thymidine kinase (tk) incorporation	Intracellular activation of prodrugs	Phase I	Tumor bed post-resection	Completed	Sandmair et al., 2000
HSV-1: G207	γ134.5 gene deletion and lacZ insertion in UL39	Protein phosphatase 1a and disrupted IFN pathway	Phase I	Intratumoral	Completed	Markert et al., 2000
HSV-1: G207	γ134.5 gene deletion and lacZ insertion in UL39	Protein phosphatase 1a and disrupted IFN pathway	Phase IB	Intratumoral and tumor bed post-resection	Completed	Markert et al., 2009
RV: Reovirus Wild type	None	Activated Ras pathway	Phase I	Intratumoral	Completed	NCT00528684 (Forsyth et al., 2008)

Abbreviations

Ad

adenovirus

E1B

adenovirus E1B protein

p53

protein 53

Ad5

human adenovirus serotype 5

RGD

arginyl-glycyl-aspartic acid motif

E1A

adenovirus early region 1A

Rb

retinoblastoma protein

CED

convection enhanced delivery

AdV

adenovirus

tk

thymidine kinase

GCV

ganciclovir

RV

reovirus

IFN

interferon

Ras

Ras pathway.